Fibrostenosis Focused Therapeutics - RFP
Funds development of innovative, non-surgical therapies for fibrostenosis in Crohn’s disease and ulcerative colitis, advancing new approaches for fibrotic IBD complications.
Funder: Crohn's and Colitis Foundation
Due Dates: May 31, 2026 (Preproposal) | June 30, 2026 (Letter of Intent) | August 14, 2026 (Full Proposal)
Funding Amounts: Up to $450,000 per project for one year; potential for renewal if milestones are met; indirect costs capped at 10%.
Summary: Funds development of innovative, non-surgical therapies for fibrotic complications in IBD, targeting fibrostenosis in Crohn’s disease and ulcerative colitis.
Key Information: Preproposal required for full proposal invitation; both for-profit companies and academic groups with commercialization focus are eligible.
Description
This opportunity seeks proposals for the development of non-surgical therapeutic products to treat or prevent fibrostenosis (fibrotic strictures) in patients with inflammatory bowel disease (IBD), specifically Crohn’s disease and ulcerative colitis. Projects should be grounded in clinical observations or published human IBD evidence and are expected to advance innovative approaches that modulate fibrotic pathways or employ multidisciplinary strategies. The goal is to address the significant unmet need for effective, non-surgical treatments for fibrotic complications in IBD, moving beyond surgical interventions.
